Navigation Links
Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
Date:1/22/2008

TORONTO, Jan. 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated in the research and development of pharmaceutical products and technologies for the management of cancer, announced today that it has strengthened its management team with the appointment of Mr. Peter Korth to the post of Chief Financial Officer (CFO).

Mr. Korth has previously held senior financial and business development positions including CFO in several private and public companies including DRI Capital (formerly known as Drug Royalty Corp.), Clean Power Income Fund, TransAlta Corporation and Indal Limited where he has been responsible for capital and credit markets, transaction structuring, managing subsidiary reorganizations, risk management practices as well as international business development in Asia and Australia.

"Mr. Korth brings significant expertise in corporate finance, investor relations, corporate governance and compliance to the management team at Lorus," said Dr. Aiping Young, Lorus' President and CEO. "We believe Lorus will benefit from Peter's track record in developing and bringing an exemplary combination of business judgment, professional skills and integrity."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, security holder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics' recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for 4325231 Canada Inc.


'/>"/>
SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... research is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets ... convened more than 100 clinical trial leaders from over 40 sponsor, CRO and site ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the ... on December 3rd, 2016. The event, which is held on the United Nations International ... Americans with Disabilities back into the workplace. Suitable Technologies is partnering with NTI to ...
(Date:12/2/2016)... , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 ...
(Date:11/30/2016)... November 30, 2016 The global ... players hold a dominant share in the overall market. ... International, Inc., and Merck KGaA, held a lion,s share ... Market Research observes that these companies are expected to ... products that are do not require rabbit pyrogen testing ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):